Literature DB >> 24607716

Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study.

Luigi Di Biase1, Fiorenzo Gaita2, Elisabetta Toso2, Pasquale Santangeli3, Prasant Mohanty4, Neal Rutledge5, Xue Yan4, Sanghamitra Mohanty4, Chintan Trivedi4, Rong Bai4, Justin Price4, Rodney Horton4, G Joseph Gallinghouse4, Salwa Beheiry4, Jason Zagrodzky4, Robert Canby4, Jean François Leclercq6, Franck Halimi7, Marco Scaglione8, Federico Cesarani9, Riccardo Faletti10, Javier Sanchez4, J David Burkhardt4, Andrea Natale11.   

Abstract

BACKGROUND: Silent cerebral ischemia (SCI) has been reported in 14% of cases after catheter ablation of atrial fibrillation (AF) with radiofrequency (RF) energy and discontinuation of warfarin before AF ablation procedures.
OBJECTIVE: The purpose of this study was to determine whether periprocedural anticoagulation management affects the incidence of SCI after RF ablation using an open irrigated catheter.
METHODS: Consecutive patients undergoing RF ablation for AF without warfarin discontinuation and receiving heparin bolus before transseptal catheterization (group I, n = 146) were compared with a group of patients who had protocol deviation in terms of maintaining the therapeutic preprocedural international normalized ratio (patients with subtherapeutic INR) and/or failure to receive pretransseptal heparin bolus infusion and/or ≥2 consecutive ACT measurements <300 seconds (noncompliant population, group II, n = 134) and with a group of patients undergoing RF ablation with warfarin discontinuation bridged with low molecular weight heparin (group III, n = 148). All patients underwent preablation and postablation (within 48 hours) diffusion magnetic resonance imaging.
RESULTS: SCI was detected in 2% of patients (3/146) in group I, 7% (10/134) in group II, and 14% (21/148) in group III (P <.001). "Therapeutic INR" was strongly associated with a lower prevalence of postprocedural silent cerebral ischemia (SCI). Multivariable analysis demonstrated nonparoxysmal AF (odds ratio 3.8, 95% confidence interval 1.5-9.7, P = .005) and noncompliance to protocol (odds ratio 2.8, 95% confidence interval 1.5-5.1, P <.001] to be significant predictors of ischemic events.
CONCLUSION: Strict adherence to an anticoagulation protocol significantly reduces the prevalence of SCI after catheter ablation of AF with RF energy.
Copyright © 2014 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ablation; Atrial fibrillation; Periprocedural; Radiofrequency; Silent cerebral ischemia; Stroke; Warfarin

Mesh:

Substances:

Year:  2014        PMID: 24607716     DOI: 10.1016/j.hrthm.2014.03.003

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  28 in total

1.  Association between left atrial low-voltage area, serum apoptosis, and fibrosis biomarkers and incidence of silent cerebral events after catheter ablation of atrial fibrillation.

Authors:  Patrick Müller; Johannes Maier; Johannes-Wolfgang Dietrich; Sebastian Barth; Daniel P Griese; Fabian Schiedat; Attila Szöllösi; Philipp Halbfass; Karin Nentwich; Markus Roos; Joachim Krug; Anja Schade; Rainer Schmitt; Andreas Mügge; Thomas Deneke
Journal:  J Interv Card Electrophysiol       Date:  2015-06-06       Impact factor: 1.900

2.  Effect of pre-procedural interrupted apixaban on heparin anticoagulation during catheter ablation for atrial fibrillation: a prospective observational study.

Authors:  Aref A Bin Abdulhak; Kevin F Kennedy; Sanjaya Gupta; Michael Giocondo; Brian Ramza; Alan P Wimmer
Journal:  J Interv Card Electrophysiol       Date:  2015-08-21       Impact factor: 1.900

3.  Safety and efficacy of novel oral anticoagulants in the setting of atrial fibrillation ablation: Is it time to celebrate the "funeral" of warfarin?

Authors:  Luigi Di Biase
Journal:  J Interv Card Electrophysiol       Date:  2014-09-17       Impact factor: 1.900

4.  Complications from catheter ablation of atrial fibrillation: impact of current and emerging ablation technologies.

Authors:  Nikhil C Panda; Jim W Cheung
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-10

Review 5.  Periprocedural Anticoagulation Management for Atrial Fibrillation Ablation: Current Knowledge and Future Directions.

Authors:  Alan Sugrue; Konstantinos C Siontis; Jonathan P Piccini; Peter A Noseworthy
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-01-25

Review 6.  The Impact of Advances in Atrial Fibrillation Ablation Devices on the Incidence and Prevention of Complications.

Authors:  Fehmi Keçe; Katja Zeppenfeld; Serge A Trines
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-08

Review 7.  Pulmonary Vein Isolation with the Multipolar nMARQ™ Ablation Catheter: Efficacy And Safety In Acute And Long-Term Follow Up.

Authors:  Johannes Siebermair; Michelle Silver; Reza Wakili
Journal:  J Atr Fibrillation       Date:  2017-04-30

8.  Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients.

Authors:  Anne-Céline Martin; Sarah Lessire; Isabelle Leblanc; Anne-Sophie Dincq; Ivan Philip; Isabelle Gouin-Thibault; Anne Godier
Journal:  Clin Cardiol       Date:  2018-05-10       Impact factor: 2.882

9.  Hyperacute And Chronic Changes In Cerebral Magnetic Resonance Images After Pvac, nmarq And Epicardial Thoracoscopic Surgical Ablation For Paroxysmal Atrial Fibrillation.

Authors:  Conn Sugihara; Neil Barlow; Emma Owens; David Sallomi; Neil Sulke
Journal:  J Atr Fibrillation       Date:  2016-04-30

10.  Immediate post-procedure bridging with unfractioned heparin versus low molecular weight heparin in patients undergoing radiofrequency ablation for atrial fibrillation with an interrupted oral anticoagulation strategy.

Authors:  Gerard Loughlin; Tomás Datino Romaniega; Javier Garcia-Fernandez; David Calvo; Ricardo Salgado; Andres Alonso; Xin Li; Angel Arenal; Esteban González-Torrecilla; Felipe Atienza; Francisco Fernández-Avilés
Journal:  J Interv Card Electrophysiol       Date:  2016-01-06       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.